Elzovantinib
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2019 (NCT03993873)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CSF1R inhibitor
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
- SRCINHIBITOR
SRC inhibitor
- Tyrosine-protein kinase Fyn (FYN) ↗
- Proto-oncogene tyrosine-protein kinase Src (SRC) ↗
- Tyrosine-protein kinase Lck (LCK) ↗
- Tyrosine-protein kinase Yes (YES1) ↗
- Tyrosine-protein kinase Blk (BLK) ↗
- Tyrosine-protein kinase HCK (HCK) ↗
- Tyrosine-protein kinase Lyn (LYN) ↗
- Tyrosine-protein kinase FRK (FRK) ↗
- Tyrosine-protein kinase Fgr (FGR) ↗
- Tyrosine-protein kinase Srms (SRMS) ↗
Chemistry & pharmacology
Loading structure…
SMILES
CCN1Cc2c(ccc(F)c2C#N)O[C@@H](C)CNC(=O)c2c(N)nn3ccc1nc23- Mol. weight
- 409.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095061 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03993873 | Phase 1 | Dec 31, 2019 | Turning Point Therapeutics |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Turning Point Therapeutics | For profit | 1 | 1 | 1 | 2019 |
1 organizations
Page 1 / 1